Krahn M D, Berka C, Langlois P, Detsky A S
Department of Medicine, University of Toronto, Ontario.
CMAJ. 1996 Mar 15;154(6):821-31.
To calculate the direct and indirect costs of asthma in Canada.
Cost-of-illness study.
Canada.
All Canadians receiving inpatient or outpatient care for asthma in 1990.
Direct costs incurred by inpatient care, emergency services, physician and nursing services, ambulance use, drugs and devices, outpatient diagnostic tests, research and education. Indirect costs from productivity loss due to absence from work, inability to to perform housekeeping activities, need to care for children with asthma who were absent from school, time spent travelling and waiting for medical care, and premature death from asthma. All costs are in 1990 Canadian dollars.
Depending on assumptions, the total cost of asthma was estimated to be between $504 million and $648 million. Direct costs were $306 million. The single largest component of direct costs was the cost of drugs ($124 million). The largest component of indirect costs was illness-related disability ($76 million).
Annual costs of treating asthma are comparable to the individual cost of infectious diseases, hematological diseases, congenital defects, perinatal illnesses, home care and ambulance services. Asthma costs may increase in the future, given current morbidity and mortality trends. Further evaluation of the effectiveness and cost-effectiveness of available asthma interventions in addition to aggregate cost data are required to determine whether resource allocation for the treatment of asthma can be improved.
计算加拿大哮喘的直接和间接成本。
疾病成本研究。
加拿大。
1990年所有因哮喘接受住院或门诊治疗的加拿大人。
住院治疗、急诊服务、医生和护理服务、救护车使用、药品和器械、门诊诊断检查、研究与教育产生的直接成本。因误工、无法进行家务活动、需要照顾患哮喘而缺课的儿童、花费在就医途中和等待上的时间以及哮喘导致的过早死亡造成的生产力损失带来的间接成本。所有成本均以1990年加拿大元计算。
根据假设,哮喘的总成本估计在5.04亿加元至6.48亿加元之间。直接成本为3.06亿加元。直接成本中最大的单项是药品成本(1.24亿加元)。间接成本中最大的部分是与疾病相关的残疾(7600万加元)。
治疗哮喘的年度成本与传染病、血液疾病、先天性缺陷、围产期疾病、家庭护理和救护车服务的个体成本相当。鉴于当前的发病率和死亡率趋势,哮喘成本未来可能会增加。除了总成本数据外,还需要进一步评估现有哮喘干预措施的有效性和成本效益,以确定哮喘治疗的资源分配是否可以改善。